文献速递病毒性肝炎

抗病毒治疗对乙型肝炎病毒整合及肝细胞克隆扩增的影响

Effect of Antiviral Treatment on Hepatitis B Virus Integration and Hepatocyte Clonal Expansion.
PubMed 文献 · Clin Infect Dis · 2023-01-01

本研究纳入28例接受核苷(酸)类似物(NUC)治疗(拉米夫定11例、替比夫定7例、恩替卡韦10例)的慢性乙型肝炎患者,基线与第1年行肝活检,其中7例第10年行第三次活检。结果显示NUC治疗可降低HBV DNA整合频率和肝细胞克隆大小,支持长期NUC治疗以预防肝细胞癌。

要点

  • 所有患者基线均可检测到HBV整合,中位整合频率为每肝1.01×10^9,肝细胞克隆大小为2.41×10^5。
  • 治疗1年后HBV整合仍可检测到,中位整合频率为每肝5.74×10^8(较基线降低0.22 log,P=.008),肝细胞克隆大小为1.22×10^5(较基线降低0.40 log,P=.002)。
  • 治疗第10年HBV整合仍可检测到,中位整合频率为每肝4.84×10^7(较基线降低0.93 log),肝细胞克隆大小为2.55×10^4(较基线降低1.02 log)。

核心结论

  • NUCs可降低HBV DNA整合和肝细胞克隆扩增,提示除直接抑制病毒外,还存在降低肝细胞癌风险的另一种替代途径。
  • 研究结果支持长期NUC治疗以预防肝细胞癌的观点。

研究设计与样本

  • 纳入28例接受NUCs治疗的患者(拉米夫定11例、替比夫定7例、恩替卡韦10例)。
  • 所有患者基线和第1年行肝活检,其中7例在第10年行第三次活检。
  • 采用反向聚合酶链反应评估HBV DNA整合和肝细胞克隆大小。

主要发现

  • 所有患者基线均可检测到HBV整合,中位整合频率为每肝1.01×10^9,肝细胞克隆大小为2.41×10^5。
  • 整合频率和肝细胞克隆大小均与年龄及HBV病毒学参数不相关。
  • 治疗1年后HBV整合仍可检测到,中位整合频率为每肝5.74×10^8(较基线降低0.22 log,P=.008),肝细胞克隆大小为1.22×10^5(较基线降低0.40 log,P=.002)。
  • 治疗第10年HBV整合仍可检测到,中位整合频率为每肝4.84×10^7(较基线降低0.93 log),肝细胞克隆大小为2.55×10^4(较基线降低1.02 log)。
  • 从基线至第1年再到第10年,整合频率和肝细胞克隆大小均呈下降趋势(P分别为.066和.018)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study investigated the effect of nucleos(t)ide analogue (NUC) treatment on hepatitis B virus (HBV) DNA integration and hepatocyte clonal expansion, both of which are implicated in hepatocellular carcinoma (HCC) in chronic hepatitis B. METHODS: Twenty-eight patients receiving NUCs (11 lamivudine, 7 telbivudine, 10 entecavir) were included. All had liver biopsies at baseline and year 1, and 7 had a third biopsy at year 10. HBV DNA integration and hepatocyte clone size were assessed by inverse polymerase chain reaction. RESULTS: All patients had detectable HBV integration at baseline, with a median integration frequency of 1.01 × 109 per liver and hepatocyte clone size of 2.41 × 105. Neither integration frequency nor hepatocyte clone size correlated with age and HBV virologic parameters. After 1 year of treatment, HBV integration was still detectable in all patients, with a median of 5.74 × 108 integration per liver (0.22 log reduction; P = .008) and hepatocyte clone size of 1.22 × 105 (0.40 log reduction; P = .002). HBV integration remained detectable at year 10 of treatment, with a median integration frequency of 4.84 × 107 integration per liver (0.93 log reduction from baseline) and hepatocyte clone size of 2.55 × 104 (1.02 log reduction from baseline). From baseline through year 1 to year 10, there was a decreasing trend in both integration frequency and hepatocyte clone size (P = .066 and.018, respectively). CONCLUSIONS: NUCs reduced both HBV DNA integration and hepatocyte clonal expansion, suggesting another alternative pathway besides direct viral suppression to reduce HCC risk. Our findings supported the notion for a long-term NUC treatment to prevent HCC.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chow N, Wong D, Lai CL, et al. Effect of Antiviral Treatment on Hepatitis B Virus Integration and Hepatocyte Clonal Expansion. Clin Infect Dis. 2023. PMID: 35594553. doi:10.1093/cid/ciac383

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。